Drug Interactions between dihydroxyaluminum sodium carbonate and Turalio
This report displays the potential drug interactions for the following 2 drugs:
- dihydroxyaluminum sodium carbonate
- Turalio (pexidartinib)
Interactions between your drugs
dihydroxyaluminum sodium carbonate pexidartinib
Applies to: dihydroxyaluminum sodium carbonate and Turalio (pexidartinib)
Talk to your doctor before using pexidartinib together with dihydroxyaluminum sodium carbonate. Dihydroxyaluminum sodium carbonate can interfere with the absorption of pexidartinib and reduce its effectiveness if they are taken too close together. In some cases, your doctor may want to prescribe alternatives that do not interact. Otherwise, you may be able to minimize the interaction by taking pexidartinib at least 2 hours before or 2 hours after dihydroxyaluminum sodium carbonate. Contact your doctor if your condition worsens during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
dihydroxyaluminum sodium carbonate food
Applies to: dihydroxyaluminum sodium carbonate
Citrate, or citric acid, can increase the absorption of dihydroxyaluminum sodium carbonate. This may lead to elevated blood levels of aluminum, particularly in individuals with reduced kidney function, since aluminum is primarily eliminated by the kidneys. Excess aluminum may deposit and cause problems in various tissues including bone, brain, heart, liver, muscles, and spleen. Over time, weak bones, bone pain, fractures, skeletal deformity, brain disorders, and anemia may develop. Talk to your doctor before using dihydroxyaluminum sodium carbonate if you have kidney impairment or are on hemodialysis. You should avoid or limit the consumption of citrate-containing foods and beverages (e.G., soft drinks, citrus fruits, fruit juices) during treatment with dihydroxyaluminum sodium carbonate. Be aware that some effervescent and dispersible drug formulations may also contain citrate and should be restricted as well. Even if you do not have kidney problems, it may be best to separate the dosing of dihydroxyaluminum sodium carbonate and citrate-containing products by 2 to 3 hours. Talk to a healthcare professional if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
When dihydroxyaluminum sodium carbonate is taken during enteral nutrition therapy (tube feeding), the tube may get clogged. Therefore, dihydroxyaluminum sodium carbonate should not be mixed with or given after high-protein tube feedings. The dose should be separated from the feeding by as much as possible, and the tube should be thoroughly flushed before administration of the dose.
pexidartinib food
Applies to: Turalio (pexidartinib)
You may experience reduced absorption of pexidartinib in the presence of food. Pexidartinib should be taken on an empty stomach at least 1 hour before or 2 hours after food. This will make it easier for your body to absorb the medication. Also, while taking pexidartinib, you should avoid grapefruits and grapefruit juice. Grapefruit and grapefruit juice can raise the levels of pexidartinib in your body and lead to potentially dangerous adverse effects. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.